Review on raloxifene: Profile of a selective estrogen receptor modulator

International Journal of Clinical Pharmacology and Therapeutics

Volumn 41, Issue 8, 2003, Pages 331-345

  Heringa, M ^a,b  

^a UNIVERSITY OF ULM   (Germany)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Breast cancer; Coronary heart disease; Osteoporosis; Raloxifene

Indexed keywords

ANTIESTROGEN; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CONJUGATED ESTROGEN; ESTROGEN DERIVATIVE; GESTAGEN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PLASMA PROTEIN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; VITAMIN D; WARFARIN;

BONE; BONE DENSITY; BONE MINERAL; BREAST CANCER; CANCER RISK; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENDOMETRIUM; ESTROGEN ACTIVITY; FEMALE; FIRST PASS EFFECT; GASTROINTESTINAL SYMPTOM; GLUCURONIDATION; HOT FLUSH; HUMAN; LEG CRAMP; MASTALGIA; OSSIFICATION; OSTEOLYSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; THROMBOEMBOLISM; URINARY EXCRETION; UTERUS CANCER; VAGINA BLEEDING;

EID: 0043076440     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP41331     Document Type: Review

References (90)

1. Adachi J, Crans G, Lu Y et al 2001 Raloxifene decreases the risk of new moderate or severe vertebral fractures in postmenopausal women with osteoporosis. Arthritis Rheum 44 (Suppl): S255
2. Allerheiligen S, Geiser J, Knadler M et al 1996 Raloxifene (RAL) pharmacokinetics and the associated endocrine effects in premenopausal women treated during the follicular, ovulatory, and luteal phases of the menstrual cycle. Pharm Res 13 (Suppl): S430
3. Altkorn D, Vokes T 2001 Treatment of postmenopausal osteoporosis. JAMA 285: 1415-1418
4. Anghel S, Perly V, Melançon G et al 2000 Aspartate 351 of estrogen receptor α is not crucial for the antagonist activity of antiestrogens. J Biol Chem 275: 20867-20872
5. Barret-Connor E, Grady D, Sashegyi A et al 2002 Raloxifene and cardiovascular events in postmenopausal women; four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 287: 847-857
6. Bjarnason N, Delmas P, Mitlak B 1998 Raloxifene maintains favourable effects on bone mineral density, bone turnover and serum lipids without endometrial stimulation in postmenopausal women. Three-year results. Osteoporos Int 8 (Suppl 3): 11
7. Black D, Sarkar S, Mitlak B, Knickerbocker R, Cummings S 1999 What proportion of the effects of raloxifene (RLX) on vertebral fracture risk can be directly attributed to its bone mineral density (BMD) effects? J Bone Miner Res 14 (Suppl 1): S158
8. Blum A, Schenke W, Hathaway L et al 2000 Effects of estrogen and the selective estrogen receptor modulator raloxifene on markers of inflammation in postmenopausal women. Am J Cardiol 86: 892-895
9. Bryant H 2001 Mechanism of action and preclinical profile of raloxifene, a selective estrogen receptor modulator. Rev Endocr Metab Disord 2: 129-138
10. Buzdar A, Marcus C, Holmes F, Hug V, Hortobagyi G 1988 Phase II evaluation of Ly156758 in metastatic breast cancer. Oncology 45: 344-345
11. Cauley J, Norton L, Lippman M et al 2001 Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat 65: 125-134
12. Chapurlat R, Ewing S, Bauer D, Cummings S 2001 Influence of smoking on the antiosteoporotic efficacy of raloxifene. J Clin Endocrinol Metab 86: 4178-4182
13. Christodoulacos G, Panoulis C, Botsis D, Rizos D, Kassanos D, Creatsas G 2002 Transvaginal sonographic monitoring of the uterine effects of raloxifene and a continuous combined replacement therapy in postmenopausal women. Maturitas 42: 77-84
14. Clemett D, Spencer C 2000 Raloxifene. A review of its use in postmenopausal osteoporosis. Drugs 60: 379-411
15. Cohen F, Watts S, Shah A, Akers R, Plouffe L 2000 Uterine effects of 3-year raloxifene therapy in postmenopausal women younger than age 60. Obstet Gynecol 95: 104-110
16. Cowley S, Hoare S, Mosselman S, Parker M 1997 Estrogen receptors α and β form heterodimers on DNA. J Biol Chem 272: 19858-19862
17. Cox D, Sashegyi A, Paul S et al 1999 Effects of raloxifene and hormone replacement therapy on markers of inflammation in healthy postmenopausal women. Circulation 100 (Suppl 1): I826
18. Cummings S, Eckert S, Krueger K et al 1999 The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 281: 2189-2197
19. Davies G, Huster W, Lu Y, Plouffe L, Lakshmanan M 1999 Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol 93: 558-565
20. De Valk-de Roo G, Stehouwer C, Meyer P 1999 Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy, postmenopausal women. Arterioscler Thromb Vasc Biol 19: 2993-3000
21. De Leo V, la Marca A, Morgante G, Lanzetta D, Setacci C, Petraglia F 2001 Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women. Am J Obstet Gynecol 184: 350-353
22. Delmas P, Bjarnason N, Mitlak B et al 1997 Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women. N Engl J Med 337: 1641-1647
23. Dodge J, Lugar C, Cho S et al 1997 Evaluation of the major metabolites of raloxifene as modulators of tissue selectivity. J Steroid Biochem Molec Biol 61: 97-106
24. Doran P, Riggs B, Atkinson E, Khosla S 2001 Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men. J Bone Miner Res 16: 2118-2125
25. Dören M, Samsioe G 2000 Prevention of postmenopausal osteoporosis with estrogen replacement therapy and associated compounds: update on clinical trials since 1995. Hum Reprod Update 6: 419-426
26. Dowsett M, Bundred N, Decensi A et al 2001 Effect of raloxifene on breast cancer cell ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients. Cancer Epidemiol Biomarkers Prev 10: 961-966
27. Draper M, Boss S, Huster W, Neild J 1994 Effects of raloxifene hydrochloride on serum markers of bone and lipid metabolism - dose-response relationships. Calcif Tissue Int 54: 339
28. Draper M, Flowers D, Neild J, Huster W, Zerbe R 1995 Antiestrogenic properties of raloxifene. Pharmacology 50: 209-217
29. Draper M, Flowers D, Huster W, Neild J, Harper K, Arnaud C 1996 A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 11: 835-842
30. Eastell R, Adachi J, Harper K et al 2000 The effects of raloxifene on incident vertebral fractures in postmenopausal women with osteoporosis: 4-year results from the MORE trial. J Bone Miner Res 15 (Suppl 1): S229
31. Eli Lilly and Company 2000 Full prescribing information Evista, raloxifene hydrochloride 60 mg tablets. Literature revised October 30 (Internet 12 September 2001)
32. Ettinger B, Black D, Mitlak B et al 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene; results from a 3-year randomized clinical trial. JAMA 282: 637-645
33. Fisher B, Costantino J, Wickerham D et al 1998 Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 90: 1371-1388
34. Forgue S, Rudy A, Knadler M et al 1996 Raloxifene pharmacokinetics in healthy postmenopausal women. Pharm Res 13 (Suppl): S429
35. Fugère P, Scheele W, Shah A, Strack T, Glant M, Jolly E 2000 Uterine effects of raloxifene in comparison with continuous-combined hormone replacement therapy in postmenopausal women. Am J Obstet Gynecol 182: 568-574
36. Gallagher J 2001 Role of estrogens in the management of postmenopausal bone loss. Rheum Dis Clin North Am 27: 143-162
37. Gize E, Venugopalan M, Glasebrook A, Yang N 1997 Characterization of raloxifene binding and transactivation properties of the estrogen receptor beta (ERβ). J Bone Miner Res 12 (Suppl 1): S460
38. Gleason C, Baker L, Cholerton B et al 2001 Effects of raloxifene on verbal memory in women with Alzheimer's disease. http://caldoc/doc1, program number 546.17, Nov 2001
39. Goldstein S, Scheele W, Rajagopalan S, Wilkie J, Walsh B, Parkons A 2000 A 12-month comparative study of raloxifene, estrogen and placebo on the postmenopausal endometrium. Obstet Gynecol 95: 95-103
40. Gradishar W, Glusman J, Lu Y, Vogel C, Cohen F, Sledge G 2000 Effects of high-dose raloxifene in selected patients with advanced breast carcinoma. Cancer 88: 2047-2053
41. Gustafsson J-Å 1999 Estrogen receptor β - a new dimension in estrogen mechanism of action. J Endocrinol 163: 379-383
42. Heaney R, Draper M 1997 Raloxifene and estrogen: comparative bone-remodeling kinetics. J Clin Endocrinol Metab 82: 3425-3429
43. Hernandez E, Valera R, Teran J et al 2000 The effect of raloxifene, a selective estrogen receptor modulator (SERM), on bone resorption markers and serum lipids in postmenopausal women on chronic hemodialysis (HD). J Am Soc Nephrol 11: 563A-564A, abstract A2974
44. Hochner-Celnikier D 1999 Pharmacokinetics of raloxifene and its clinical application. Eur J Obstet Gynecol Reprod Biol 85: 23-29
45. Http://139.133.7.20/medicine_therapeutics/bone/boneteaching.hti
46. Http://www.protherics.com/crunch/section7.html
47. Johnell O, Scheele W, Lu Y, Lakshmanan M 1999 Effects of raloxifene (RLX), alendronate (ALN) and RLX+ALN on bone mineral density (BMD) and biochemical markers of bone turnover in postmenopausal women with osteoporosis. J Bone Miner Res 14 Suppl 1): S157
48. Johnell O, Scheele W, Lu Y, Reginster J-Y, Need A, Seeman E 2002 Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87: 985-992
49. Johnston J, Bjarnason N, Cohen F et al 2000 Long-term effects of raloxifene on bone mineral density, bone turnover and serum lipid levels in early postmenopausal women. Arch Intern Med 160: 3444-3450
50. Jordan V, Glusman J, Eckert S et al 1998 Raloxifene reduces incident primary breast cancers: integrated data from multicenter, double-blind, placebo-controlled, randomized trials in postmenopausal women. Breast Cancer Tes Treat 50: 227
51. Jordan V, Morrow M 1999 Tamoxifen, raloxifene and the prevention of breast cancer. Endocr Rev 20: 253-278
52. Jordan V, Gapstur S, Morrow M 2001 Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis and coronary heart disease. J Natl Cancer Inst 93: 1449-1457
53. Katzenellenbogen B, Katzenellenbogen J 2002 Defining the "S" in SERMs. Science 295: 2380-2381
54. Kemp D, Fan P, Stevens J 2002 Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. Drug Metab Dispos 30: 694-700
55. 14C-labeled raloxifene in humans. Pharm Res 12 (Suppl): S372
56. Krishnan V, Heath H, Bryant H 2000 Mechanisms of action of estrogens and selective estrogen receptor modulators. Vitam Horm 60: 123-147
57. Kuiper G, Gustafsson J-Å 1997 The novel estrogen receptor-β subtype: potential role in the cell- and promoter-specific actions of estrogens and anti-estrogens. FEBS Letters 410: 87-90
58. Lord S, Lu Y, Lakshaman M, Wong M, Scheele W 1999 Raloxifene does not affect neuromuscular function or the incidence of falls in postmenopausal women with osteoporosis. Menopause 6: 347
59. Lufkin E, Whitaker M, Nickelsen T et al 1998 Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J Bone Miner Res 13: 1747-1754
60. Macgregor J, Jordan V 1998 Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 50: 151-196
61. Meunier P, Vignot E, Garnero P et al 1999 Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Osteoporos Int 10: 330-336
62. Miller J, Skerjanec A, Knadler M, Ghosh A, Allerheiligen S 2001 Divergent effects of raloxifene, HCl on the pharmacokinetics and pharmacodynamics of warfarin. Pharm Res 18: 1024-1028
63. Morgan S 2001 Calcium and vitamin D in osteoporosis. Rheum Dis Clin North Am 27: 101-130
64. Mosca L, Harper K, Sarkar S et al 2001 Effect of raloxifene on serum triglycerides in postmenopausal women: influence of predisposing factors for hypertriglyceridemia. Clin Ther 23: 1552-1565
65. Mosselman S, Polman J, Dijkema R 1996 ERβ: identification and characterization of a novel human estrogen receptor. FEBS Lett 392: 49-53
66. Neele S, Rombouts S, Bierlaagh M, Barkhof F, Scheltens P, Netelenbos J 2001 Raloxifene affects brain activation patterns in postmenopausal women during visual encoding. J Clin Endocrinol Metab 86: 1422-1424
67. Neele S, Evertz R, Genazzani A, Luisi M, Netelenbos C 2002 Raloxifene treatment increases plasma levels of β-endorphin in postmenopausal women: a randomized, placebo-controlled study. Fertil Steril 77: 1110-1117
68. Ni L, Allerheiligen S, Basson R et al 1996 Pharmacokinetics of raloxifene in men and postmenopausal women volunteers. Pharm Res 13 (Suppl): S430
69. Nickelsen T, Lufkin E, Riggs B, Cox D, Crook T 1999 Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women. Psychoneuroendocrinology 24: 115-128
70. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis and Therapy 2001 Osteoporosis prevention, diagnosis and therapy. JAMA 285: 785-795
71. Ott S, Oleksik A, Lu Y, Harper K, Lips P 2002 Bone histomorphometric and biochemical marker results of a 2-year placebo-controlled trial of raloxifene in postmenopausal women. J Bone Miner Res 17: 341-348
72. Paech K, Webb P, Kuiper G et al 1997 Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science 277: 1508-1510
73. Pavo I, Masanauskaite D, Rojinskaya L et al 1999 Effects of raloxifene (RLX) vs. placebo (PL) on bone mineral density (BMD) in postmenopausal women in the absence of calcium supplementation. J Bone Miner Res 14 (Suppl 1): S410
74. Pfeifer M, Lehmann R, Minne H 2001 Die Therapie der Osteoporose aus dem Blickwinkel einer auf Evidenz basierenden Medizin. Med Klin 96: 270-280
75. Prestwood K, Gunness M, Muchmore D, Lu Y, Wong M, Raisz L 2000 A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. J Clin Endocrinol Metab 85: 2197-2202
76. Saitta A, Altavilla D, Cucinotta D et al 2001 Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma NO concentrations, endothelin-1 levels and endothelium-dependent vasodilation in postmenopausal women. Arterioscler Thromb Vasc Biol 21: 1512-1519
77. Sarkar S, Mitlak B, Wong M, Stock J, Black D, Harper K 2002 Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17: 1-10
78. Shang Y, Brown M 2002 Molecular determinants for the tissue specificity of SERMs. Science 295: 2465-2468
79. Sharpe M, Noble S, Spencer C 2001 Alendronate; an update of its use in osteoporosis. Drugs 61: 999-1039
80. Smolders R, Vogelvang T, Mijatovic V et al 2002 A 2-year, randomized, comparative, placebo-controlled study on the effects of raloxifene on lipoprotein(a) and homocysteine. Maturitas 41: 105-114
81. Stephen AB, Wallace WA 2001 The management of osteoporosis. J Bone Joint Surg Br 83: 316-323
82. Strickler R, Stovall D, Merritt D, Shen W, Wong M, Silfen S 2000 Raloxifene and estrogen effects on quality of life in healthy postmenopausal women: a placebo-controlled randomized trial. Obstet Gynecol 96: 359-365
83. Uebelhart B, Bonjour J, Draper M, Pavo I, Basson R, Rizzoli R 2000 Effects of the selective estrogen receptor modulator raloxifene (RLX) on bone metabolism in healthy males. J Bone Miner Res 15 (Suppl 1): S229
84. Walker-Bone K, Dennison E, Cooper C 2001 Epidemiology of osteoporosis. Rheum Dis Clin North Am 27: 1-18
85. Walsh B, Kuller L, Wild A et al 1998 Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 279: 1445-1451
86. Walsh B, Paul S, Wild R et al 2000 The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 85: 214-218
87. Walsh B, Cox D, Sashegyi A, Dean A, Tracy R, Anderson P 2001 Role of tumor necrosis factor-α and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women. Am J Cardiol 88: 825-828
88. Yaffe K, Krueger K, Sarkar S et al 2001 Cognitive function in postmenopausal women treated with raloxifene. N Engl J Med 344: 1207-1213
89. Yang N, Venugopalan M, Hardikar S, Glasebrook A 1996 Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene. Science 273: 1222-1225
90. Yang N, Venugopalan M, Hardikar S, Glasebrook A 1997 Letter: Correction: Raloxifene response needs more than an element. Science 275: 1249